Med. praxi 2012; 9(8-9): 342-346

Schizophrenia: diagnostics and current therapeutic options

doc.MUDr.Pavel Mohr, Ph.D.
Psychiatrické centrum Praha
3. lékařská fakulta UK, Praha

Psychotic disorders are characterized by a loss of touch with reality. The most important disorder from the group is schizophrenia,

illness resulting in severe functional impairment. Diagnosis is based primarily on clinical symptomatology and exclusion of other

etiology, either organic or toxic. Treatment of schizophrenia is complex, combining pharmacotherapy and psychosocial interventions.

Antipsychotics represent the causal therapy. Currently, the most frequently prescribed drugs are so called atypical antipsychotics. The

profile of side effects depends on the antipsychotic receptor affinity. Metabolic side effects and weight gain are gaining more attention,

replacing traditional movement disorders (EPS) and hyperprolactinemia. Thus, it is of utmost importance to monitor closely physical

condition of patients treated with antipsychotics. The treatment is long-term, not only restricted to acute phase; maintenance therapy

for relapse prevention is essential. In case of low adherence with drug treatment, long-term acting injection formulas of antipsychotic

can be administered.

Keywords: psychosis, schizophrenia, diagnostics, therapy, antipsychotics

Published: September 25, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mohr P. Schizophrenia: diagnostics and current therapeutic options. Med. praxi. 2012;9(8-9):342-346.
Download citation

References

  1. Mohr P. Psychózy. In: Herman E, a kol. Konziliární psychiatrie. Medical Tribune 2007: 74-78.
  2. World Health Organization. Mezinárodní klasifikace nemocí - 10. revize. Duševní poruchy a poruchy chování. Psychiatrické centrum Praha 2006 (3. vydání), 251 pp.
  3. Mohr P. Schizofrenie. In: Horáček J. Psychotické stavy v klinické praxi. Academia Medica Pragensis 2003: 31-57.
  4. Wittchen HU, Jacobi F, Rehm J,  et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679. Go to original source... Go to PubMed...
  5. Olesen J, Gustavsson A, Svensson M,  et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012; 19: 155-162. Go to original source... Go to PubMed...
  6. Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010; 24(Suppl 4): 17-25. Go to original source... Go to PubMed...
  7. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62: 247-253. Go to original source... Go to PubMed...
  8. Hippisley-Cox  J, Parker C, Coupland C, et al. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart 2007; 93: 1256-1262. Go to original source... Go to PubMed...
  9. Laursen TM, Munk-Olsen T, Agerbo E, et al. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 200 9; 66: 713-20.
  10. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia,, ,just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009; 110: 1-23. Go to original source... Go to PubMed...
  11. Keshavan MS, Nasrallah HA, Tandon R. Schizophrenia,, ,Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr Res 2011; 127: 3-13. Go to original source... Go to PubMed...
  12. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia,, ,just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010; 122: 1-23. Go to original source... Go to PubMed...
  13. Spaniel F, Vohlídka P, Hrdlicka J, et al. ITAREPS: information technology aided relapse prevention programme in schizophrenia. Schizophr Res 2008; 98: 312-317. Go to original source... Go to PubMed...
  14. Tůma I. Farmakologická léčba schizofrenie. Psychiatrie 2011; 15: 96-103.
  15. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 31-41. Go to original source... Go to PubMed...
  16. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-163. Go to original source... Go to PubMed...
  17. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370. Go to original source... Go to PubMed...
  18. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627. Go to original source... Go to PubMed...
  19. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005; 73: 139-145. Go to original source... Go to PubMed...
  20. Mohr P, Volavka J. Adherence a depotní antipsychotika v léčbě schizofrenie. Psychiatrie 2011; 15: 105-113.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.